BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26868083)

  • 1. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.
    Kapczynski DR; Tumpey TM; Hidajat R; Zsak A; Chrzastek K; Tretyakova I; Pushko P
    Vaccine; 2016 Mar; 34(13):1575-1581. PubMed ID: 26868083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks.
    Prel A; Le Gall-Reculé G; Jestin V
    Avian Pathol; 2008 Oct; 37(5):513-20. PubMed ID: 18798027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge.
    Bublot M; Pritchard N; Cruz JS; Mickle TR; Selleck P; Swayne DE
    Avian Dis; 2007 Mar; 51(1 Suppl):498-500. PubMed ID: 17494618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype.
    Pavlova SP; Veits J; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Aug; 27(37):5085-90. PubMed ID: 19573638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam.
    Tian G; Zeng X; Li Y; Shi J; Chen H
    Avian Dis; 2010 Mar; 54(1 Suppl):287-9. PubMed ID: 20521646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
    Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.
    Song H; Nieto GR; Perez DR
    J Virol; 2007 Sep; 81(17):9238-48. PubMed ID: 17596317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.
    Bright RA; Carter DM; Crevar CJ; Toapanta FR; Steckbeck JD; Cole KS; Kumar NM; Pushko P; Smith G; Tumpey TM; Ross TM
    PLoS One; 2008 Jan; 3(1):e1501. PubMed ID: 18231588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.
    Pushko P; Tretyakova I; Hidajat R; Sun X; Belser JA; Tumpey TM
    Vaccine; 2018 Jul; 36(29):4346-4353. PubMed ID: 29885769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements to the hemagglutination inhibition test for serological assessment of recombinant fowlpox-H5-avian-influenza vaccination in chickens and its use along with an agar gel immunodiffusion test for differentiating infected from noninfected vaccinated animals.
    Swayne DE; Avellaneda G; Mickle TR; Pritchard N; Cruz J; Bublot M
    Avian Dis; 2007 Sep; 51(3):697-704. PubMed ID: 17992929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and use of fowlpox vectored vaccines for avian influenza.
    Bublot M; Pritchard N; Swayne DE; Selleck P; Karaca K; Suarez DL; Audonnet JC; Mickle TR
    Ann N Y Acad Sci; 2006 Oct; 1081():193-201. PubMed ID: 17135511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.
    Giles BM; Bissel SJ; Dealmeida DR; Wiley CA; Ross TM
    Clin Vaccine Immunol; 2012 Feb; 19(2):128-39. PubMed ID: 22190399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
    Rauw F; Palya V; Van Borm S; Welby S; Tatar-Kis T; Gardin Y; Dorsey KM; Aly MM; Hassan MK; Soliman MA; Lambrecht B; van den Berg T
    Vaccine; 2011 Mar; 29(14):2590-600. PubMed ID: 21292007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus.
    Kilany WH; Abdelwhab EM; Arafa AS; Selim A; Safwat M; Nawar AA; Erfan AM; Hassan MK; Aly MM; Hafez HM
    Vet Microbiol; 2011 May; 150(1-2):28-34. PubMed ID: 21236607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.
    Jiang Y; Yu K; Zhang H; Zhang P; Li C; Tian G; Li Y; Wang X; Ge J; Bu Z; Chen H
    Antiviral Res; 2007 Sep; 75(3):234-41. PubMed ID: 17451817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks.
    Prel A; Le Gall-Reculé G; Cherbonnel M; Grasland B; Amelot M; Jestin V
    Avian Dis; 2007 Mar; 51(1 Suppl):484-9. PubMed ID: 17494615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.